Sickle Cell Disease and Deferasirox Iron Chelation

Deferasirox in iron overload from chronic transfusion in sickle-cell disease: rationale, dosing, monitoring and public-health context.

Sickle-cell disease (SCD) is one of the largest indications for chronic transfusion globally. Patients on regular transfusion programmes for stroke prevention, recurrent acute chest syndrome or other complications develop transfusional iron overload that requires effective long-term chelation - which is the role of deferasirox.

Why Patients with SCD Receive Chronic Transfusion #

  • Primary stroke prevention in children with abnormal transcranial Doppler velocities (STOP / TWiTCH protocols).
  • Secondary stroke prevention after a clinical or silent infarct.
  • Recurrent acute chest syndrome not controlled by hydroxyurea.
  • Selected complications such as pulmonary hypertension and progressive sickle nephropathy.

Distinct Iron-Overload Pattern in SCD #

Compared with thalassemia, SCD patients may have:

  • Lower iron-driven cardiac risk in some series (less cardiac iron loading at equivalent ferritin levels)
  • More variable hepatic iron distribution due to chronic inflammation
  • Higher baseline inflammation, which can elevate ferritin independently of iron stores - making LIC by MRI especially valuable

Deferasirox in SCD #

Deferasirox is approved for chronic iron overload in SCD on transfusion programmes in many markets. Dosing typically follows transfusional thalassemia: starting around 20 mg/kg/day with the dispersible formulation, titrated by serum ferritin and LIC trends. Serial LIC measurement (preferred over ferritin alone) guides dose decisions in the inflamed-state patient.

Tolerability Considerations in SCD #

SCD patients can have baseline renal involvement (sickle nephropathy) - careful renal monitoring before and during deferasirox therapy is essential. Hyperhydration, careful blood-pressure control, and avoidance of nephrotoxic combinations are recommended.

Public-Health Burden #

Sickle-cell disease is one of the most common monogenic disorders worldwide, with a particularly high prevalence in sub-Saharan Africa, parts of the Middle East, India and the Caribbean. Reliable, regulator-compliant supply of oral iron chelators is therefore a public-health priority. Taj Pharma supplies DEFRATAJ across these regions through tender programmes, NGOs and private channels - see the Africa page.